Akesis names John L. Capicchioni as new president

Thursday, May 31, 2012 12:34 PM

Akesis, a Lake Wylie, S.C.-based contract research firm specializing in phase II-IV clinical dermatology services and regulatory affairs consulting, has appointed John L. Capicchioni as its new president.

Capicchioni will be responsible for providing strategic leadership and managerial oversight of the company while driving growth and assuring quality, cost optimization and best business practices to pharmaceutical, device, generic, formulation development and biotechnology companies.

Capicchioni brings 22 years of global CRO experience to Akesis. He has held a broad range of executive leadership positions, overseeing global sales, project management, marketing and client services. He has served as senior vice president of business development for global early clinical and bioanalytical research at MDS Pharma Services (now Celerion), where he directed the pharmaceutical and generic segments. He has also held senior posts at Phoenix International Life Sciences. Capicchioni has also served on the board of directors of the Generic Pharmaceutical Association as the elected member for CROs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs